Premium
The lymphomas: Response to irradiation
Author(s) -
Fayos Juan V.,
Edlund John H.,
Knapp William T.,
Campos Jose L.,
Lampe Isadore
Publication year - 1974
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197407)34:1<212::aid-cncr2820340132>3.0.co;2-4
Subject(s) - reticulum cell sarcoma , medicine , lymphoma , sarcoma , disease , mantle cell lymphoma , radiation therapy , irradiation , pathology , physics , nuclear physics
Four hundred eighty‐four patients with lymphoma received initial irradiation at the University of Michigan from the years 1960 through 1971. No patient with staging celiotomy was included. The distribution was as follows: Hodgkin's disease, 46.9%; lymphosarcoma, 26.7%; reticulum cell sarcoma, 23.5%; and unclassified lymphoma, 2.9%. In most instances, only involved regions were irradiated in the non‐Hodgkin's lymphomas. Hodgkin's disease was treated regionally, but in supradiaphragmatic disease, adjacent areas received prophylactic irradiation, in recent years with the use of a mantle. Present doses vary between 3500–4500 rad given in 4 to 5 weeks. Complications were minimal. The reactivation‐free interval at 6 years for Stages I and II nodal was 41%, 32%, and 31% for Hodgkin's, lymphosarcoma, and reticulum cell sarcoma. A non‐nodal component on first reactivation was found in 24% of Hodgkin's, 33% of lymphosarcoma, and 41% of reticulum cell sarcoma. In these two groups, systematic total nodal irradiation probably would have had no potential benefit. The authors conclude that limited irradiation in early stages (after staging celiotomy) has merits.